Heart Failure Leads Cardio Device Regulatory Activity In Near Term
Congestive heart failure is among the leading indications with regulatory catalysts expected in the next two years, driven by ventricular assist devices. Data from Informa's MedDeviceTracker.
You may also be interested in...
Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.
Principle investigator on the Evolve II trial is optimistic the stent will dominate the U.S. market in two to three years.
The firm announced the first U.S. implant for its investigational Micra transcatheter, leadless pacing system, and the global launch of its miniature Reveal LINQ implantable cardiac monitor.